Arca
Skip to content

Bronchiectasis

Drug research and approvals for bronchiectasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 94 studies of bronchiectasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 11 drug trials for it since 2013, FDA has 1 approved and 8 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 94
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 1
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 94 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

9 in phase 3, 3 in phase 2, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Ciprofloxacin
Phase 3 Bacterial DNA gyrase inhibitor
Roflumilast
Phase 3 Phosphodiesterase 4 inhibitor
Mannitol
Phase 3 Unknown
Azithromycin
Phase 3 Bacterial 70S ribosome inhibitor
Brensocatib
Phase 3 Dipeptidyl peptidase I inhibitor
Itraconazole
Phase 3 Cytochrome P450 51 inhibitor
Beclomethasone dipropionate
Phase 3 Glucocorticoid receptor agonist
Formoterol
Phase 3 Beta-2 adrenergic receptor agonist
Carbocysteine
Phase 3 Unknown
Tobramycin
Phase 2 70S ribosome inhibitor
Aztreonam
Phase 2 Bacterial penicillin-binding protein inhibitor
Alvelestat
Phase 2 Leukocyte elastase inhibitor
Human immunoglobulin g
Phase 1 Replacement therapy, immunomodulatory effects
ALX-009
Phase 1
Icenticaftor
Phase 1 Cystic fibrosis transmembrane conductance regulator activator

How Its Trials Ended

330 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 60 whose ending is known, 45% met their primary endpoint, 8% missed it and 47% stopped early.

  • Completed, result not reported11836%
  • Ongoing7723%
  • Status unknown7523%
  • Met its primary endpoint278%
  • Stopped: other or unclear155%
  • Missed its primary endpoint52%
  • Stopped: lack of efficacy31%
  • Stopped: enrollment or feasibility31%
  • Stopped: sponsor or business decision31%
  • Stopped: funding31%
  • Stopped: safety10%

Trials Authorized in Canada

The 10 newest of 11; search them all in Canada trials
Nov 10, 2026A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose range finding study to evaluate the efficacy, safety, and…CSL787CSLPending
Mar 20, 2026A randomized, double-blinded, placebo-controlled, parallel-group, phase 2a participants with non-cystic fibrosis bronchiectasis (ncfb) study to assess the…SAR445399Sanofi-Aventis Canada IncOngoing
Aug 21, 2025A phase IIb randomized, double-blind, placebo-controlled, parallel, multidose study to evaluate the efficacy, safety, and pk of azd0292 in participants 12…AZD0292AstraZeneca Pharmaceuticals LPOngoing
Apr 15, 2025A phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of bi 1291583 2.5 mg administered once daily…Verducatib (bi 1291583)Boehringer Ingelheim (Canada) Ltd LteeOngoing
Feb 28, 2024A randomized, double-blind, placebo-controlled, parallel group, proof-ofconcept (poc) study to assess the efficacy, safety and tolerability of itepekimab, in…Itepekimab (SAR440340; REGN3500)Sanofi-Aventis Canada IncClosed
May 16, 2023A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of bi 1291583 q.d. in patients with…BI 1291583Boehringer Ingelheim (Canada) Ltd LteeOngoing
Feb 4, 2021A multicentre, randomised, double-blind, parallel-group, placebo-controlled, 52 week, phase III study with an open-label extension to evaluate the efficacy and…Benralizumab (MEDI-563)AstraZeneca Pharmaceuticals LPOngoing
Dec 3, 2020A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of brensocatib administered once daily for 52…Brensocatib (INS1007)InsmedClosed
Jan 31, 2018A double-blind, placebo controlled, multi-center, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled promixin®…ColistimethateZambonClosed
Apr 17, 2014A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pulmaquin® in the management of chronic lung…PulmaquinAradigm Corp.Closed

FDA Orphan Designations

Approved first, then open designations, newest first
Oct 30, 2020Bronchitol®As add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use…Pharmaxis Europe LimitedApproved
Feb 14, 2014DoxofyllineTreatment of bronchiectasisAlitair Pharmaceuticals, Inc.Designated
Dec 20, 2013ErdosteineTreatment of bronchiectasisEdmond Pharma S.r.l.Designated
Jun 1, 2011CiprofloxacinThe management of bronchiectasisSavara Inc.Designated
Apr 3, 2008Alpha1-antitrypsin(human)Treatment of bronchiectasisKamada Ltd.Designated
Dec 27, 2006Liposomal ciprofloxacin for inhalationManagement of bronchiectasisSavara Inc.Designated
Aug 28, 2001Recombinant human alpha-1 antitrypsin (rAAT)To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasisAiroMedica LLCDesignated
Jun 18, 1999TobramycinTreatment of bronchiectasis patients infected with Pseudomonas aeruginosa.Novartis Pharmaceuticals Corp.Designated
Mar 6, 1995Recombinant human gelsolinTreatment of acute and chronic respiratory symptoms of bronchiectasis.BioAgeis, Therapeutics, Inc.Designated

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Nov 18, 2025BrinsupriBrensocatibInsmed Netherlands B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.